Your browser doesn't support javascript.
loading
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes, Javier; Cescon, David W; Rugo, Hope S; Nowecki, Zbigniew; Im, Seock-Ah; Yusof, Mastura Md; Gallardo, Carlos; Lipatov, Oleg; Barrios, Carlos H; Holgado, Esther; Iwata, Hiroji; Masuda, Norikazu; Otero, Marco Torregroza; Gokmen, Erhan; Loi, Sherene; Guo, Zifang; Zhao, Jing; Aktan, Gursel; Karantza, Vassiliki; Schmid, Peter.
Afiliação
  • Cortes J; International Breast Cancer Center, Quiron Group, Madrid and Barcelona, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain. Electronic address: jacortes@vhio.net.
  • Cescon DW; Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Rugo HS; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, USA.
  • Nowecki Z; Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
  • Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
  • Yusof MM; Pantai Hospital, Kuala Lumpur, Malaysia.
  • Gallardo C; Arturo Lopez Perez Foundation, Santiago, Chile.
  • Lipatov O; Republican Clinical Oncology Dispensary, Republic of Bashkortostan, Russia.
  • Barrios CH; Oncology Research Unit, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil.
  • Holgado E; International Breast Cancer Center, Quiron Group, Madrid and Barcelona, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Iwata H; Aichi Cancer Center Hospital, Nagoya, Japan.
  • Masuda N; National Hospital Organization, Osaka National Hospital, Osaka, Japan.
  • Otero MT; Oncomedica, Monteria, Colombia.
  • Gokmen E; Ege University Medical Faculty, Izmir, Turkey.
  • Loi S; Peter McCallum Cancer Centre, Melbourne, VIC, Australia.
  • Guo Z; Merck, Kenilworth, NJ, USA.
  • Zhao J; Merck, Kenilworth, NJ, USA.
  • Aktan G; Merck, Kenilworth, NJ, USA.
  • Karantza V; Merck, Kenilworth, NJ, USA.
  • Schmid P; Barts Cancer Institute, Centre for Experimental Cancer Medicine and Queen Mary University of London, London, UK.
Lancet ; 396(10265): 1817-1828, 2020 12 05.
Article em En | MEDLINE | ID: mdl-33278935
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Neoplasias de Mama Triplo Negativas / Antineoplásicos Imunológicos / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Neoplasias de Mama Triplo Negativas / Antineoplásicos Imunológicos / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2020 Tipo de documento: Article